Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Future Oncology (London, England)|January 24, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationaleElisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, et al.
Oncotarget|November 22, 2017
Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatmentMarzia Del Re, Paola Bordi, Iacopo Petrini, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|November 12, 2024
Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinomaFilippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, et al.
Stem Cell Reports|June 20, 2017
The Developmental Stage of Adult Human Stem Cell-Derived Retinal Pigment Epithelium Cells Influences Transplant Efficacy for Vision RescueRichard J Davis, Nazia M Alam, Cuiping Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2026
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Pageof 11